Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01544114 · ClinicalTrials.gov registry record · Phase 4
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A Phase 4 study of Juvenile Idiopathic Arthritis (JIA), sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
- 17
- Study locations
NCT01544114: Completed Phase 4 study of Juvenile Idiopathic Arthritis (JIA), sponsored by Amgen.
NCT01544114 is a Phase 4 study of Juvenile Idiopathic Arthritis (JIA) that has completed, run by Amgen. The registered enrollment target is 46 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01544114, a Phase 4 study of Juvenile Idiopathic Arthritis (JIA), has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
- 17
- Study locations
Study Summary
A 6-month study of the safety of VIMOVO in adolescents aged 12 to 16 years with JIA.
Primary Outcome
An AE is defined as the development of an undesirable medical condition or the deterioration of a preexisting medical condition, whether or not considered causally related to treatment. An SAE is defined as an AE occurring during any study phase (ie, run-in, treatment, washout, follow-up), that fulfils one or more of the following criteria: results in death; is immediately life-threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or
Conditions Studied
Interventions
- DRUG VIMOVO 250/20
- DRUG VIMOVO 375/20
- DRUG VIMOVO 500/20
Study Locations (17)
New York
- Research Site - Brooklyn
- Research Site - New Hyde Park
- Research Site - New York
Ohio
- Research Site - Cincinnati
- Research Site - Cleveland
- Research Site - Toledo
Arkansas
- Research Site - Little Rock
California
- Research Site - San Francisco
Colorado
- Research Site - Aurora
District of Columbia
- Research Site - Washington D.C.
Florida
- Research Site - West Palm Beach
Georgia
- Research Site - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-02 |
| Phase | Phase 4 |
What the finished NCT01544114 record still lists
NCT01544114 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Juvenile Idiopathic Arthritis (JIA) appearing as the primary indexed condition, and to 3 interventions - of which VIMOVO 250/20 is the first listed.
NCT01544114 lists 17 locations in 13 states (New York, Ohio, Arkansas).
Frequently Asked Questions
What is clinical trial NCT01544114 about?
NCT01544114 is a clinical study titled "A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)". A 6-month study of the safety of VIMOVO in adolescents aged 12 to 16 years with JIA.
What is the current status of trial NCT01544114?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2012-04. Estimated completion is 2015-02.
What conditions does trial NCT01544114 study?
This clinical trial studies the following conditions: Juvenile Idiopathic Arthritis (JIA).
What interventions are being tested in trial NCT01544114?
The interventions under investigation include: VIMOVO 250/20 (DRUG), VIMOVO 375/20 (DRUG), VIMOVO 500/20 (DRUG).
Who is sponsoring clinical trial NCT01544114?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01544114 being conducted?
This trial has 17 study locations across Arkansas, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Idiopathic Arthritis (JIA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01544114's enrollment target sits among peer trials
46 1348th of 2000 higher than 648 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia